WK Hofmann, HP Koeffler, 2004 - Annual Reviews During the past 15 years, important progress has been made in the understanding
of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal
disorder characterized by ineffective hematopoiesis, which can lead to ... Cited by 84 - Related articles - BL Direct - All 10 versions
- ►bloodjournal.org Y Saunthararajah, R Nakamura, R Wesley, QJ … - Blood, 2003 - Am Soc Hematology Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be
used to treat the cytopenia associated with myelodysplastic syndrome (MDS).
Previously, we identified HLA-DR15, younger age, and shorter duration of ... Cited by 80 - Related articles - BL Direct - All 5 versions
- ►mayoclinicproceedings.com DP Steensma, JM Bennett - Mayo Clinic Proceedings, 2006 - mayoclinicproceedings.com The myelodysplastic syndromes (MDSs) are common, acquired, clinically
challenging hematologic conditions that are characterized by bone marrow failure
and a risk of progression to acute leukemia. These disorders can arise de ... Cited by 68 - Related articles - BL Direct - All 8 versions
- ►hematologylibrary.org G Mufti, AF List, SD Gore, AYL Ho - Hematology, 2003 - asheducationbook.hematologylibrary.org The last decade has witnessed a multistep evolution in the understanding of the
natural history, clinical manifestations, and some of the molecular mechanisms
that underlie the ineffective hematopoiesis and leukemic transformation in ... Cited by 63 - Related articles - All 5 versions
- ►bloodjournal.org [PDF] DP Steensma, A Dispenzieri, SB Moore, G … - Blood, 2003 - Am Soc Hematology The myelodysplastic syndrome (MDS) includes a heterogeneous group of marrow
disorders characterized by ineffective hematopoi- esis and a variable risk of
leukemic transformation. Because most patients with MDS are diagnosed after ... Cited by 55 - Related articles - All 6 versions
M Stadler, U Germing, KO Kliche, KM Josten, … - Leukemia, 2004 - nature.com Immunosuppression has recently been proposed for low-risk myelodysplastic
syndromes (MDS) to reverse bone marrow failure by inhibiting intramedullary
secretion of proapoptotic cytokines. We treated 35 MDS patients (24 ... Cited by 52 - Related articles - All 3 versions
- ►hematologylibrary.org - Free from Publisher EM Sloand, L Mainwaring, M Fuhrer, S … - Blood, 2005 - bloodjournal.hematologylibrary.org Clinical observations and experimental evidence link bone marrow failure in
myelodysplastic syndrome (MDS) with a T cell–dominated autoimmune process.
Immunosuppressive therapy is effective in improving cytopenias in selected ... Cited by 47 - Related articles - BL Direct - All 6 versions
- ►alphamedpress.org MG Rose, N Berliner - The Oncologist, 2004 - AlphaMed Press T-cell large granular lymphocyte (LGL) leukemia is a clonal proliferation of
cytotoxic T cells, which causes neutropenia, anemia, and/or thrombocytopenia.
This condition is often associated with autoimmune disorders, especially ... Cited by 44 - Related articles - All 12 versions
S Faderl, HM Kantarjian - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 41 - Related articles - BL Direct - All 3 versions
DVT Catenacci, GJ Schiller - Blood reviews, 2005 - Elsevier Myelodysplastic syndromes (MDS) are a set of oligoclonal disorders of
hematopoietic stem cells characterized by ineffective hematopoiesis that
manifest clinically as anemia, neutropenia, and/or thrombocytopenia of ... Cited by 41 - Related articles - All 8 versions
